10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALZN (Alzamend) Stock Analysis
Buy, Hold or Sell?

Let's analyze Alzamend together

I guess you are interested in Alzamend Neuro Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Alzamend’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Alzamend’s Price Targets

I'm going to help you getting a better view of Alzamend Neuro Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Alzamend Neuro Inc

I send you an email if I find something interesting about Alzamend Neuro Inc.

1. Quick Overview

1.1. Quick analysis of Alzamend (30 sec.)










1.2. What can you expect buying and holding a share of Alzamend? (30 sec.)

How much money do you get?

How much money do you get?
$0.02
When do you have the money?
1 year
How often do you get paid?
2.8%

What is your share worth?

Current worth
$1.26
Expected worth in 1 year
$3.28
How sure are you?
30.6%

+ What do you gain per year?

Total Gains per Share
$2.03
Return On Investment
81.7%

For what price can you sell your share?

Current Price per Share
$2.49
Expected price per share
$2.227 - $3.6
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Alzamend (5 min.)




Live pricePrice per Share (EOD)
$2.49
Intrinsic Value Per Share
$-6.44 - $-6.72
Total Value Per Share
$-5.18 - $-5.45

2.2. Growth of Alzamend (5 min.)




Is Alzamend growing?

Current yearPrevious yearGrowGrow %
How rich?$3.9m-$2.3m$4.8m196.2%

How much money is Alzamend making?

Current yearPrevious yearGrowGrow %
Making money-$1.1m-$2.4m$1.3m120.3%
Net Profit Margin0.0%-279.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Alzamend (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#637 / 853

Most Revenue
#743 / 853

Most Profit
#255 / 853

Most Efficient
#210 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Alzamend?

Welcome investor! Alzamend's management wants to use your money to grow the business. In return you get a share of Alzamend.

First you should know what it really means to hold a share of Alzamend. And how you can make/lose money.

Speculation

The Price per Share of Alzamend is $2.49. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alzamend.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alzamend, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.26. Based on the TTM, the Book Value Change Per Share is $0.50 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.42 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alzamend.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.36-14.6%-0.31-12.5%-0.76-30.7%-0.75-29.9%-0.72-29.1%-0.51-20.3%
Usd Book Value Change Per Share0.6425.6%0.5020.3%-0.42-17.0%-0.25-10.0%0.052.0%0.041.4%
Usd Dividend Per Share0.000.0%0.000.2%0.000.0%0.000.1%0.000.0%0.000.0%
Usd Total Gains Per Share0.6425.6%0.5120.4%-0.42-17.0%-0.25-9.9%0.052.0%0.041.4%
Usd Price Per Share0.66-1.73-0.94-1.17-1.15-0.64-
Price to Earnings Ratio-0.45--1.46--0.39--0.68--0.54--0.30-
Price-to-Total Gains Ratio1.03-2.28--0.78-0.16--0.13--0.13-
Price to Book Ratio0.52--1.36--4.22--1.72--0.93--0.52-
Price-to-Total Gains Ratio1.03-2.28--0.78-0.16--0.13--0.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.49
Number of shares401
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.500.05
Usd Total Gains Per Share0.510.05
Gains per Quarter (401 shares)203.8920.41
Gains per Year (401 shares)815.5581.64
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1680980618072
213161816223161154
319242824384241236
425323732545321318
532404640706402400
638485548868482482
744566457029563564
8516474651810643646
9577283733411723728
10638092815013804810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.036.00.00.0%0.036.00.00.0%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%7.011.02.035.0%11.015.010.030.6%11.015.010.030.6%
Dividend per Share1.00.03.025.0%1.00.011.08.3%1.00.019.05.0%1.00.035.02.8%1.00.035.02.8%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%7.011.02.035.0%11.015.010.030.6%11.015.010.030.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Alzamend Neuro Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6390.504+27%-0.425+166%-0.249+139%0.050+1175%0.035+1719%
Book Value Per Share--1.2640.641+97%-0.735+158%0.708+78%1.317-4%0.862+47%
Current Ratio--6.5814.077+61%0.348+1794%3.417+93%5.243+26%5.053+30%
Debt To Asset Ratio--0.1380.572-76%3.949-97%1.593-91%1.172-88%1.135-88%
Debt To Equity Ratio--0.1600.176-9%-+100%0.198-19%0.279-43%0.499-68%
Dividend Per Share---0.004-100%-0%0.001-100%0.001-100%0.000-100%
Enterprise Value--1437546.6007059350.700-80%63598.261+2160%5347637.590-73%8953477.499-84%8953477.499-84%
Eps---0.363-0.312-14%-0.764+111%-0.745+105%-0.724+100%-0.507+40%
Ev To Ebitda Ratio---0.319-1.638+413%0.022-1572%-0.759+138%-1.005+215%-1.005+215%
Free Cash Flow Per Share---0.286-0.462+61%-0.633+121%-0.594+107%-0.506+77%-0.342+19%
Free Cash Flow To Equity Per Share--0.1880.290-35%-0.352+287%-0.249+233%0.071+164%0.041+360%
Gross Profit Margin--1.0031.067-6%1.088-8%1.068-6%1.041-4%1.051-5%
Intrinsic Value_10Y_max---6.716----------
Intrinsic Value_10Y_min---6.441----------
Intrinsic Value_1Y_max---2.131----------
Intrinsic Value_1Y_min---2.094----------
Intrinsic Value_3Y_max---5.292----------
Intrinsic Value_3Y_min---5.074----------
Intrinsic Value_5Y_max---7.113----------
Intrinsic Value_5Y_min---6.697----------
Market Cap7818251.400+73%2072307.6006272444.450-67%3094797.761-33%4008411.590-48%3836038.149-46%2131132.305-3%
Net Profit Margin----0%-2.7970%-0.9320%-0.5590%-0.4980%
Operating Margin----0%-2.7920%-0.9310%-0.5580%-0.4980%
Operating Ratio----0%2.792-100%0.931-100%0.558-100%0.549-100%
Pb Ratio1.970+73%0.522-1.358+360%-4.224+909%-1.724+430%-0.931+278%-0.517+199%
Pe Ratio-1.715-277%-0.455-1.464+222%-0.393-14%-0.683+50%-0.542+19%-0.301-34%
Price Per Share2.490+73%0.6601.734-62%0.944-30%1.165-43%1.155-43%0.642+3%
Price To Free Cash Flow Ratio-2.175-277%-0.576-1.135+97%-0.467-19%-0.633+10%-0.621+8%-0.345-40%
Price To Total Gains Ratio3.899+73%1.0332.281-55%-0.784+176%0.161+542%-0.133+113%-0.133+113%
Quick Ratio---2.076-100%0.216-100%2.548-100%4.495-100%2.961-100%
Return On Assets---0.248-0.338+37%-2.192+785%-0.989+299%-0.801+224%-0.871+252%
Return On Equity---0.287-0.238-17%--100%-0.299+4%-0.420+46%-0.761+165%
Total Gains Per Share--0.6390.508+26%-0.425+166%-0.248+139%0.051+1155%0.036+1697%
Usd Book Value--3968222.0002489663.500+59%-2395845.500+160%2437456.500+63%4264660.650-7%2776198.417+43%
Usd Book Value Change Per Share--0.6390.504+27%-0.425+166%-0.249+139%0.050+1175%0.035+1719%
Usd Book Value Per Share--1.2640.641+97%-0.735+158%0.708+78%1.317-4%0.862+47%
Usd Dividend Per Share---0.004-100%-0%0.001-100%0.001-100%0.000-100%
Usd Enterprise Value--1437546.6007059350.700-80%63598.261+2160%5347637.590-73%8953477.499-84%8953477.499-84%
Usd Eps---0.363-0.312-14%-0.764+111%-0.745+105%-0.724+100%-0.507+40%
Usd Free Cash Flow---898705.000-1694546.500+89%-2067498.000+130%-1997610.833+122%-1670190.250+86%-1118421.861+24%
Usd Free Cash Flow Per Share---0.286-0.462+61%-0.633+121%-0.594+107%-0.506+77%-0.342+19%
Usd Free Cash Flow To Equity Per Share--0.1880.290-35%-0.352+287%-0.249+233%0.071+164%0.041+360%
Usd Market Cap7818251.400+73%2072307.6006272444.450-67%3094797.761-33%4008411.590-48%3836038.149-46%2131132.305-3%
Usd Price Per Share2.490+73%0.6601.734-62%0.944-30%1.165-43%1.155-43%0.642+3%
Usd Profit---1139445.000-1128611.250-1%-2486882.250+118%-2445473.917+115%-2337754.250+105%-1625805.056+43%
Usd Revenue----0%19027.500-100%6342.500-100%3805.500-100%8695.944-100%
Usd Total Gains Per Share--0.6390.508+26%-0.425+166%-0.248+139%0.051+1155%0.036+1697%
 EOD+6 -2MRQTTM+16 -19YOY+25 -103Y+24 -135Y+21 -1610Y+26 -11

3.3 Fundamental Score

Let's check the fundamental score of Alzamend Neuro Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.715
Price to Book Ratio (EOD)Between0-11.970
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than16.581
Debt to Asset Ratio (MRQ)Less than10.138
Debt to Equity Ratio (MRQ)Less than10.160
Return on Equity (MRQ)Greater than0.15-0.287
Return on Assets (MRQ)Greater than0.05-0.248
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Alzamend Neuro Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.490
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Alzamend Neuro Inc

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Fundamental data was last updated by Penke on 2025-08-23 10:04:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Alzamend earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Alzamend to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alzamend Neuro Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-279.7%+279.7%
TTM-5Y-55.9%+55.9%
5Y-55.9%10Y-49.8%-6.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--86.1%+86.1%
TTM--169.5%+169.5%
YOY-279.7%-209.8%-69.9%
3Y-93.2%-284.5%+191.3%
5Y-55.9%-380.6%+324.7%
10Y-49.8%-519.5%+469.7%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Alzamend is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Alzamend to theΒ Biotechnology industry mean.
  • -24.8% Return on Assets means thatΒ Alzamend generatedΒ $-0.25 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alzamend Neuro Inc:

  • The MRQ is -24.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -33.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.8%TTM-33.8%+9.0%
TTM-33.8%YOY-219.2%+185.4%
TTM-33.8%5Y-80.1%+46.3%
5Y-80.1%10Y-87.1%+7.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.8%-12.1%-12.7%
TTM-33.8%-12.0%-21.8%
YOY-219.2%-11.2%-208.0%
3Y-98.9%-12.0%-86.9%
5Y-80.1%-11.7%-68.4%
10Y-87.1%-13.8%-73.3%
4.3.1.3. Return on Equity

Shows how efficient Alzamend is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Alzamend to theΒ Biotechnology industry mean.
  • -28.7% Return on Equity means Alzamend generated $-0.29Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alzamend Neuro Inc:

  • The MRQ is -28.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -23.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.7%TTM-23.8%-4.9%
TTM-23.8%YOY--23.8%
TTM-23.8%5Y-42.0%+18.2%
5Y-42.0%10Y-76.1%+34.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.7%-14.3%-14.4%
TTM-23.8%-15.2%-8.6%
YOY--15.2%+15.2%
3Y-29.9%-16.8%-13.1%
5Y-42.0%-17.5%-24.5%
10Y-76.1%-19.6%-56.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Alzamend Neuro Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Alzamend is operatingΒ .

  • Measures how much profit Alzamend makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Alzamend to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alzamend Neuro Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-279.2%+279.2%
TTM-5Y-55.8%+55.8%
5Y-55.8%10Y-49.8%-6.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--161.5%+161.5%
TTM--286.7%+286.7%
YOY-279.2%-254.3%-24.9%
3Y-93.1%-270.1%+177.0%
5Y-55.8%-356.3%+300.5%
10Y-49.8%-528.7%+478.9%
4.3.2.2. Operating Ratio

Measures how efficient Alzamend is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.792-2.792
TTM-5Y0.558-0.558
5Y0.55810Y0.549+0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.929-1.929
TTM-2.934-2.934
YOY2.7922.982-0.190
3Y0.9313.799-2.868
5Y0.5584.893-4.335
10Y0.5496.841-6.292
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Alzamend Neuro Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Alzamend is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 6.58Β means the company has $6.58 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 6.581. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.077. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.581TTM4.077+2.504
TTM4.077YOY0.348+3.730
TTM4.0775Y5.243-1.165
5Y5.24310Y5.053+0.190
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5813.480+3.101
TTM4.0773.736+0.341
YOY0.3484.133-3.785
3Y3.4174.591-1.174
5Y5.2435.762-0.519
10Y5.0536.154-1.101
4.4.3.2. Quick Ratio

Measures if Alzamend is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Alzamend to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.00Β means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.076-2.076
TTM2.076YOY0.216+1.860
TTM2.0765Y4.495-2.419
5Y4.49510Y2.961+1.535
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.930-2.930
TTM2.0763.192-1.116
YOY0.2163.990-3.774
3Y2.5484.381-1.833
5Y4.4955.837-1.342
10Y2.9616.540-3.579
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Alzamend Neuro Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AlzamendΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Alzamend to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14Β means that Alzamend assets areΒ financed with 13.8% credit (debt) and the remaining percentage (100% - 13.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 0.138. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.572. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.138TTM0.572-0.434
TTM0.572YOY3.949-3.377
TTM0.5725Y1.172-0.600
5Y1.17210Y1.135+0.037
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1380.339-0.201
TTM0.5720.359+0.213
YOY3.9490.334+3.615
3Y1.5930.341+1.252
5Y1.1720.349+0.823
10Y1.1350.379+0.756
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Alzamend is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Alzamend to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 16.0% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 0.160. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.176. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.160TTM0.176-0.016
TTM0.176YOY-+0.176
TTM0.1765Y0.279-0.103
5Y0.27910Y0.499-0.221
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1600.391-0.231
TTM0.1760.432-0.256
YOY-0.427-0.427
3Y0.1980.462-0.264
5Y0.2790.459-0.180
10Y0.4990.514-0.015
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Alzamend generates.

  • Above 15 is considered overpriced butΒ always compareΒ Alzamend to theΒ Biotechnology industry mean.
  • A PE ratio of -0.45 means the investor is paying $-0.45Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alzamend Neuro Inc:

  • The EOD is -1.715. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.455. Based on the earnings, the company is expensive. -2
  • The TTM is -1.464. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.715MRQ-0.455-1.261
MRQ-0.455TTM-1.464+1.009
TTM-1.464YOY-0.393-1.071
TTM-1.4645Y-0.542-0.922
5Y-0.54210Y-0.301-0.241
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.715-2.542+0.827
MRQ-0.455-2.355+1.900
TTM-1.464-2.660+1.196
YOY-0.393-3.770+3.377
3Y-0.683-3.843+3.160
5Y-0.542-6.412+5.870
10Y-0.301-7.084+6.783
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alzamend Neuro Inc:

  • The EOD is -2.175. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.576. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.135. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.175MRQ-0.576-1.598
MRQ-0.576TTM-1.135+0.559
TTM-1.135YOY-0.467-0.668
TTM-1.1355Y-0.621-0.515
5Y-0.62110Y-0.345-0.276
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.175-3.327+1.152
MRQ-0.576-3.016+2.440
TTM-1.135-3.645+2.510
YOY-0.467-4.377+3.910
3Y-0.633-5.257+4.624
5Y-0.621-8.487+7.866
10Y-0.345-9.626+9.281
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Alzamend is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.52 means the investor is paying $0.52Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alzamend Neuro Inc:

  • The EOD is 1.970. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.522. Based on the equity, the company is cheap. +2
  • The TTM is -1.358. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.970MRQ0.522+1.448
MRQ0.522TTM-1.358+1.880
TTM-1.358YOY-4.224+2.866
TTM-1.3585Y-0.931-0.427
5Y-0.93110Y-0.517-0.414
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9702.201-0.231
MRQ0.5222.007-1.485
TTM-1.3582.189-3.547
YOY-4.2242.409-6.633
3Y-1.7242.558-4.282
5Y-0.9313.764-4.695
10Y-0.5174.462-4.979
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alzamend Neuro Inc.

4.8.1. Institutions holding Alzamend Neuro Inc

Institutions are holding 0.07% of the shares of Alzamend Neuro Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc0.01410397300
2025-03-31HARBOR INVESTMENT ADVISORY, LLC0.000102000
2025-03-31SBI Securities Co Ltd0.000101800
2025-03-31Parallel Advisors, LLC00300
2025-06-30Activest Wealth Management0.00010220
2025-03-31Tower Research Capital LLC000-388-100
2025-06-30BB&T Corp.000-1722-100
2025-03-31Citigroup Inc000-544-100
2025-03-31Citadel Advisors Llc000-30638-100
2025-03-31UBS Group AG000-820-100
2025-03-31Renaissance Technologies Corp000-15000-100
2025-03-31Virtu Financial LLC000-12719-100
2025-03-31Advisor Group Holdings, Inc.000-6-100
Total 0.014404016-61835-1,539.7%

4.9.2. Funds holding Alzamend Neuro Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Fidelity Extended Market Index0.10550331400
2025-06-30Fidelity Series Total Market Index0.0254079700
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.01910600-272-31.1927
2025-06-30Fidelity Nasdaq Composite Index0.0035011000
2025-06-30Fidelity Total Market Index0.002507700
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.0002068680
2025-06-30NT Ext Equity Mkt Idx Fd - NL0.0013041-1-2.381
2025-06-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.001032-1-3.0303
2025-06-30NT Ext Equity Mkt Idx Fd - L0.001031-1-3.125
2025-06-30Northern Trust Extended Eq Market Idx0.001031-1-3.125
2025-06-30Spartan Total Market Index Pool G0.000902800
2025-06-30BNYM Mellon SL Market Completion UC10.0007022-1-4.3478
2025-06-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.000309112.5
2025-06-30Northern Trust Wilshire 50000.00010300
Total 0.162505163-208-4.0%

5.3. Insider Transactions

Insiders are holding 0.811% of the shares of Alzamend Neuro Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-07-31Milton C Ault IiiSELL1000002.22
2025-07-30Milton C Ault IiiSELL294492.51
2025-07-28Milton C Ault IiiSELL83112.68
2025-07-25Milton C Ault IiiSELL365322.9
2025-07-24Milton C Ault IiiSELL96212.93
2025-07-23Milton C Ault IiiSELL595162.95
2025-03-26William B HorneBUY3708.91
2025-03-20William B HorneBUY5558.82
2025-03-18Milton C Ault IiiBUY5558.64
2025-03-12Milton C Ault IiiBUY116.12
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-04-30. Currency in USD. All numbers in thousands.

Summary
Total Assets4,603
Total Liabilities635
Total Stockholder Equity3,968
 As reported
Total Liabilities 635
Total Stockholder Equity+ 3,968
Total Assets = 4,603

Assets

Total Assets4,603
Total Current Assets4,177
Long-term Assets426
Total Current Assets
Cash And Cash Equivalents 3,949
Total Current Assets  (as reported)4,177
Total Current Assets  (calculated)3,949
+/- 229
Long-term Assets
Property Plant Equipment 426
Long-term Assets  (as reported)426
Long-term Assets  (calculated)426
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities635
Long-term Liabilities0
Total Stockholder Equity3,968
Total Current Liabilities
Accounts payable 635
Total Current Liabilities  (as reported)635
Total Current Liabilities  (calculated)635
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)3,968
Total Stockholder Equity (calculated)0
+/- 3,968
Other
Capital Stock0
Common Stock Shares Outstanding 779
Net Invested Capital 3,968
Net Working Capital 3,543



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-04-302025-01-312024-10-312024-07-312024-04-302024-01-312023-10-312023-07-312023-04-302023-01-312022-10-312022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312020-07-312020-04-302020-01-312019-10-312019-07-312019-04-302019-01-312018-10-312018-07-312018-04-302018-01-312017-10-312017-07-312017-04-302017-01-312016-10-312016-07-31
> Total Assets 
205
205
132
132
409
409
2,416
2,416
1,937
1,937
1,501
1,501
2,795
2,795
0
1,814
0
0
802
2,913
16,818
14,501
12,429
14,516
12,210
10,425
8,502
5,916
2,628
984
853
632
1,670
5,008
4,176
4,603
4,6034,1765,0081,6706328539842,6285,9168,50210,42512,21014,51612,42914,50116,8182,913802001,81402,7952,7951,5011,5011,9371,9372,4162,416409409132132205205
   > Total Current Assets 
130
130
57
57
409
409
2,416
2,416
1,937
1,937
1,501
1,501
2,795
2,795
166
1,814
90
0
802
2,913
16,818
14,501
12,429
14,414
12,115
10,334
8,417
5,836
2,414
782
594
455
1,416
4,767
3,947
4,177
4,1773,9474,7671,4164555947822,4145,8368,41710,33412,11514,41412,42914,50116,8182,9138020901,8141662,7952,7951,5011,5011,9371,9372,4162,4164094095757130130
       Cash And Cash Equivalents 
32
32
5
5
306
306
545
545
0
0
43
43
166
166
-166
90
-90
0
41
1,929
15,618
13,573
11,790
14,064
11,527
9,183
7,376
5,141
1,695
200
283
376
1,194
4,093
3,358
3,949
3,9493,3584,0931,1943762832001,6955,1417,3769,18311,52714,06411,79013,57315,6181,929410-9090-166166166434300545545306306553232
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
331
0
181
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000181033100000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
285
671
671
0
194
0
0
16
16
16
16
0
0
9
0
0
0
0
0
0
0
0
0
0
0
000000000009001616161600194067167128500000000000
       Other Current Assets 
98
98
52
52
103
103
1,871
1,871
1,936
1,936
1,458
1,458
2,630
2,630
0
1,529
0
0
745
967
1,183
912
639
350
578
1,152
1,041
695
718
582
311
79
222
674
589
0
0589674222793115827186951,0411,1525783506399121,183967745001,52902,6302,6301,4581,4581,9361,9361,8711,87110310352529898
   > Long-term Assets 
75
75
75
75
0
0
0
0
0
0
0
0
0
0
-166
0
-90
0
0
0
0
0
0
103
96
90
85
80
214
202
259
176
254
241
228
426
42622824125417625920221480859096103000000-900-166000000000075757575
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
103
96
90
85
80
214
202
189
176
254
241
228
426
4262282412541761892022148085909610300000000000000000000000
       Long-term Assets Other 
75
75
75
75
0
0
0
0
0
0
0
0
0
0
-166
0
-90
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000-900-166000000000075757575
> Total Liabilities 
109
109
717
717
455
455
97
97
440
440
1,184
1,184
585
585
0
992
0
0
2,098
900
1,473
1,475
467
1,165
1,029
1,637
2,642
2,870
2,741
3,666
5,046
3,226
2,882
1,255
726
635
6357261,2552,8823,2265,0463,6662,7412,8702,6421,6371,0291,1654671,4751,4739002,0980099205855851,1841,1844404409797455455717717109109
   > Total Current Liabilities 
109
109
717
717
455
455
97
97
440
440
1,184
1,184
585
585
0
992
0
0
2,098
900
1,473
1,475
467
1,165
1,029
1,637
2,642
2,870
2,741
3,666
3,826
3,226
2,882
1,255
726
635
6357261,2552,8823,2263,8263,6662,7412,8702,6421,6371,0291,1654671,4751,4739002,0980099205855851,1841,1844404409797455455717717109109
       Short-term Debt 
16
16
591
591
264
264
0
0
65
65
79
79
81
81
0
63
0
0
1,221
335
340
345
0
0
0
0
0
0
0
0
0
301
0
0
0
0
00003010000000003453403351,22100630818179796565002642645915911616
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
357
335
340
345
0
0
0
0
0
0
0
0
0
301
0
0
0
0
0000301000000000345340335357000000000000000000
       Accounts payable 
68
68
126
126
191
191
90
90
329
329
1,105
1,105
504
504
0
930
0
0
877
504
1,073
1,128
465
1,163
1,029
648
2,642
2,870
2,741
4
3,826
2,925
2,882
1,255
726
635
6357261,2552,8822,9253,82642,7412,8702,6426481,0291,1634651,1281,0735048770093005045041,1051,10532932990901911911261266868
       Other Current Liabilities 
25
25
0
0
0
0
7
7
45
45
0
0
0
0
0
63
0
0
864
61
61
2
2
2
1,029
989
2,642
0
2,741
3,662
3,826
2,925
2,882
1,255
726
0
07261,2552,8822,9253,8263,6622,74102,6429891,029222616186400630000045457700002525
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,473
465
1,163
1,029
648
2,642
0
0
0
1,220
0
0
0
0
0
000001,2200002,6426481,0291,1634651,473000000000000000000000
> Total Stockholder Equity
96
96
-585
-585
-46
-46
2,319
2,319
1,497
1,497
317
317
2,210
2,210
2,210
822
822
0
-1,296
2,013
15,344
13,025
11,962
13,352
11,182
8,787
5,860
3,046
-113
-2,682
-4,194
-2,594
-1,212
3,753
3,450
3,968
3,9683,4503,753-1,212-2,594-4,194-2,682-1133,0465,8608,78711,18213,35211,96213,02515,3442,013-1,29608228222,2102,2102,2103173171,4971,4972,3192,319-46-46-585-5859696
   Common Stock
12
12
3
3
14
14
5
5
5
5
6
6
6
6
0
6
0
0
6
7
9
9
9
10
10
10
10
10
10
1
1
0
0
1
1
0
0110011101010101010999760060666655551414331212
   Retained Earnings -58,535-57,396-56,410-54,995-54,020-53,169-50,506-47,600-44,073-40,767-35,342-32,232-29,194-25,325-22,752-19,152-16,832-15,57600-11,7860-9,258-9,258-7,376-7,376-5,563-5,563-2,513-2,513-1,859-1,859-1,581-1,581-783-783
   Accumulated Other Comprehensive Income 
-3
-3
0
0
0
0
0
0
0
0
-15,000
-15,000
-15,000
-15,000
2,210
-14,983
822
0
-14,883
-14,883
-14,883
-14,883
-14,883
-14,883
-14,883
-14,883
-14,883
-14,883
-14,883
-14,876
-478
0
0
0
0
0
00000-478-14,876-14,883-14,883-14,883-14,883-14,883-14,883-14,883-14,883-14,883-14,883-14,8830822-14,9832,210-15,000-15,000-15,000-15,00000000000-3-3
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,722
49,371
50,652
52,162
57,420
58,287
59,003
0
61,992
0
0
0
0
0
0
0
0
0000000061,992059,00358,28757,42052,16250,65249,37133,7220000000000000000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
870
870
993
993
1,800
1,800
4,827
4,827
7,055
7,055
22,686
22,686
26,462
26,462
0
42,567
0
0
29,156
48,605
49,371
50,652
52,162
57,420
58,287
59,003
46,617
62,001
62,361
62,700
48,974
51,426
53,782
60,162
60,845
0
060,84560,16253,78251,42648,97462,70062,36162,00146,61759,00358,28757,42052,16250,65249,37148,60529,1560042,567026,46226,46222,68622,6867,0557,0554,8274,8271,8001,800993993870870



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2025-04-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-51
Gross Profit-51-51
 
Operating Income (+$)
Gross Profit-51
Operating Expense-4,446
Operating Income-4,497-4,497
 
Operating Expense (+$)
Research Development1,415
Selling General Administrative3,082
Selling And Marketing Expenses0
Operating Expense4,4464,497
 
Net Interest Income (+$)
Interest Income0
Interest Expense-18
Other Finance Cost-0
Net Interest Income-18
 
Pretax Income (+$)
Operating Income-4,497
Net Interest Income-18
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-4,515-4,479
EBIT - interestExpense = -4,515
-4,515
-4,497
Interest Expense18
Earnings Before Interest and Taxes (EBIT)-4,497-4,497
Earnings Before Interest and Taxes (EBITDA)-4,446
 
After tax Income (+$)
Income Before Tax-4,515
Tax Provision-0
Net Income From Continuing Ops-4,515-4,515
Net Income-4,515
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses4,497
Total Other Income/Expenses Net-1818
 

Technical Analysis of Alzamend
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alzamend. The general trend of Alzamend is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alzamend's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Alzamend Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alzamend Neuro Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.75 < 2.81 < 3.6.

The bearish price targets are: 2.54 > 2.53 > 2.227.

Know someone who trades $ALZN? Share this with them.πŸ‘‡

Alzamend Neuro Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alzamend Neuro Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alzamend Neuro Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Moving Average Convergence/Divergence (MACD) ChartAlzamend Neuro Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alzamend Neuro Inc. The current adx is .

Alzamend Neuro Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Relative Strength Index (RSI) ChartAlzamend Neuro Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Stochastic Oscillator ChartAlzamend Neuro Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Commodity Channel Index (CCI) ChartAlzamend Neuro Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Chande Momentum Oscillator (CMO) ChartAlzamend Neuro Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Williams %R ChartAlzamend Neuro Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Average True Range (ATR) ChartAlzamend Neuro Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily On-Balance Volume (OBV) ChartAlzamend Neuro Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Money Flow Index (MFI) ChartAlzamend Neuro Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alzamend Neuro Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-29BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-08-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-17STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Alzamend Neuro Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alzamend Neuro Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.490
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Alzamend with someone you think should read this too:
  • Are you bullish or bearish on Alzamend? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alzamend? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alzamend Neuro Inc

I send you an email if I find something interesting about Alzamend Neuro Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Alzamend Neuro Inc.

Receive notifications about Alzamend Neuro Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.